To achieve the full impact of ChroMeta, it is essential to validate findings across both mouse and human systems. To this end, the project has contributed to the development of a streamlined and scalable stem cell based model of the human blastocyst, known as blastoids. This technological advance provides a powerful platform to test whether mechanisms identified in mouse development also operate in human early development, thereby strengthening the translational relevance of the project’s findings and providing a resource that will benefit the wider research community.
Using parallel mouse and human models, the project has uncovered key molecular pathways that enable cells to interpret their metabolic state through chromatin regulation. In particular, histone acetyltransferases—most notably P300—were identified as highly sensitive readers of cellular metabolism. In human stem cell based models, this sensitivity proved crucial during the first lineage decision. Modulating cellular metabolism altered histone acetylation dynamics, which in turn promoted specification and maturation of placental lineages. Importantly, metabolic regulation enhanced the functional properties of these placental cell types, as demonstrated in in vitro blastoid attachment assays.
Complementary findings were obtained in the mouse embryo, where both histone acetyltransferases and histone deacetylases were found to respond strongly to metabolic changes. Unexpectedly, glutamine emerged as a major metabolic fuel supporting histone acetylation. The project further identified HDAC3 as a key enzyme controlling the rapid turnover of histone acetylation, enabling chromatin to function as a robust sensor of the cellular metabolic state. Together, these results establish a direct mechanistic link between metabolism, chromatin regulation, and early developmental decisions. The work described here has resulted in three peer reviewed publication, and further finding made publicly available as preprints, ensuring early dissemination while the project is ongoing.